Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.

doi:10.1016/j.jtho.2025.04.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2025

Wiesweg Marcel, Alaffas Ali, Rasokat Anna, Saalfeld Felix Carl, Rost Maximilian, Assmann Christin, Herster Franziska, Hilbrandt Moritz, Griesinger Frank, Kron Anna, Roeper Julia, Glanemann Franziska, Kropf-Sanchen Cornelia, Reck Martin, Kulhavy Jonas, Stenzinger Albrecht, Wolf Jürgen, Sebastian Martin, Schuler Martin, Wermke Martin, Frost Nikolaj, Kopp Hans-Georg, Christopoulos Petros, Scheffler Matthias

Abstract excerpt

BACKGROUND: Targeted treatment of patients with metastatic BRAF-V600-mutated NSCLC using BRAF/MEK-inhibitors is effective but limited by acquired resistance. Patients with BRAF-mutant NSCLC may derive long-lasting benefit from immune checkpoint inhibition with programmed death-1/programmed death-ligand 1 (PD-L1) antibodies (immuno-oncology [IO]). Although IO is the preferred first-line therapy in BRAF-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunotherapy

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 40345491
DOI: 10.1016/j.jtho.2025.04.016

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.PMID 40345491Read ↗

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLCSemantic proximity Read ↗

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanySemantic proximity Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Semantic proximity Read ↗

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.Semantic proximity Read ↗

[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].Semantic proximity Read ↗

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.Semantic proximity Read ↗

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung CancerSemantic proximity Read ↗

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.